Clovis Oncology, Inc.

XTRA:C6O Stock Report

Market Cap: €12.8m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Clovis Oncology Management

Management criteria checks 3/4

Key information

Patrick Mahaffy

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage28.0%
CEO tenure13.9yrs
CEO ownership0.7%
Management average tenure7.1yrs
Board average tenure13.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Patrick Mahaffy's remuneration changed compared to Clovis Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$252m

Jun 30 2022n/an/a

-US$263m

Mar 31 2022n/an/a

-US$258m

Dec 31 2021US$3mUS$739k

-US$265m

Sep 30 2021n/an/a

-US$299m

Jun 30 2021n/an/a

-US$310m

Mar 31 2021n/an/a

-US$336m

Dec 31 2020US$3mUS$721k

-US$369m

Sep 30 2020n/an/a

-US$370m

Jun 30 2020n/an/a

-US$385m

Mar 31 2020n/an/a

-US$413m

Dec 31 2019US$7mUS$719k

-US$400m

Sep 30 2019n/an/a

-US$400m

Jun 30 2019n/an/a

-US$396m

Mar 31 2019n/an/a

-US$377m

Dec 31 2018US$6mUS$689k

-US$368m

Sep 30 2018n/an/a

-US$321m

Jun 30 2018n/an/a

-US$291m

Mar 31 2018n/an/a

-US$366m

Dec 31 2017US$9mUS$636k

-US$346m

Sep 30 2017n/an/a

-US$365m

Jun 30 2017n/an/a

-US$370m

Mar 31 2017n/an/a

-US$324m

Dec 31 2016US$789kUS$224k

-US$349m

Compensation vs Market: Patrick's total compensation ($USD2.64M) is above average for companies of similar size in the German market ($USD439.47K).

Compensation vs Earnings: Patrick's compensation has been consistent with company performance over the past year.

CEO

Patrick Mahaffy (59 yo)

13.9yrs

Tenure

US$2,639,083

Compensation

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...

Leadership Team

NamePositionTenureCompensationOwnership
Patrick Mahaffy
Co-Founder13.9yrsUS$2.64m0.67%
€ 85.6k
Daniel Muehl
Executive VP & CFO7yrsUS$1.19m0.072%
€ 9.2k
Paul Gross
Executive VP7.2yrsUS$1.20m0.068%
€ 8.7k
Lindsey Rolfe
Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer7.6yrsUS$1.24m0.078%
€ 10.0k
Thomas Harding
Executive VP & Chief Scientific Officer3.4yrsno datano data
Ann Bozeman
Executive Vice President of Human Resources6.5yrsno datano data

7.1yrs

Average Tenure

57yo

Average Age

Experienced Management: C6O's management team is seasoned and experienced (7.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Patrick Mahaffy
Co-Founder13.9yrsUS$2.64m0.67%
€ 85.6k
Paul Klingenstein
Independent Director13.9yrsUS$260.00k0.041%
€ 5.2k
Brian Atwood
Independent Director14.2yrsUS$270.00k0.040%
€ 5.1k
Edward McKinley
Independent Director14.2yrsUS$270.00k0.17%
€ 22.1k
James Blair
Independent Director14.2yrsUS$270.00k0.044%
€ 5.6k
Ginger Graham
Independent Chairman10.2yrsUS$287.50k0%
€ 0
Thorlef Spickschen
Independent Director14.2yrsUS$257.50k0.040%
€ 5.1k
Ronit Simantov
Director1.7yrsUS$375.21kno data
Keith Flaherty
Independent Director10.2yrsUS$259.58k0%
€ 0
Richard Fair
Independent Director4.4yrsUS$257.50k0%
€ 0
Robert Azelby
Independent Director4.4yrsUS$255.00k0%
€ 0

13.9yrs

Average Tenure

66yo

Average Age

Experienced Board: C6O's board of directors are seasoned and experienced ( 13.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/22 00:31
End of Day Share Price 2022/12/23 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Clovis Oncology, Inc. is covered by 18 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Alethia YoungCredit Suisse
Steven BreazzanoEvercore ISI